Tamoxifen Versus Etoposide After First Recurrence in GBM Patients

Key facts

Sponsor

AHS Cancer Control Alberta

Intervention

Tamoxifen(drug)

Enrollment

60 enrolled

Eligibility

18-65 years · All sexes

Timeline

2022 – 2027

Study locations (1)

• Cross Cancer Institute, Edmonton, Alberta, Canada

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Giant cell glioblastoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07544992
  Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
  City of Hope Medical Center
• RECRUITINGEARLY PHASE1NCT07268053
  A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases
  Nader Sanai
• RECRUITINGPHASE2NCT07511725
  Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma
  Second Affiliated Hospital, School of Medicine, Zhejiang University
• RECRUITINGPHASE3NCT07195591
  Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
  GT Medical Technologies, Inc.
• RECRUITINGPHASE2NCT07263438
  Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial
  Centre Hospitalier Universitaire Vaudois
• RECRUITINGPHASE1NCT06176066
  PH Sensitive MRI Based Resections of Glioblastoma
  University of California, Los Angeles
• RECRUITINGNANCT07121842
  Glioblastoma Imaging for the Detection of Tumor Progression Using APTw-CEST MRI
  Erasmus Medical Center
• RECRUITINGNANCT06136611
  Preoperative Preradiotherapy TTFields
  The Christie NHS Foundation Trust

See all trials for Giant cell glioblastoma →